Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06336889 · ClinicalTrials.gov registry record
Pelvic Angioembolization: A Prospective Multi-Institutional Study (Data From All Campuses Will be Used)
A clinical trial of Pelvic Hemorrhage, sponsored by Methodist Health System.
- Recruiting
- Registry status
- 400
- Enrollment target
- 1
- Study location
NCT06336889 is a study of Pelvic Hemorrhage that is actively recruiting participants, run by Methodist Health System. The registered enrollment target is 400 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06336889, a study of Pelvic Hemorrhage, is actively recruiting participants, sponsored by Methodist Health System.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigator's propose a multicenter prospective observational study to investigate the use of embolization in patients with negative angiogram and to ascertain the optimal level of treatment when the angiogram is positive; non-selective vs. selective embolization.
Conditions Studied
Interventions
- PROCEDURE Pelvic Angioembolization
Study Locations (1)
Texas
- Methodist Dallas Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2017-10-26 |
| Est. Completion | 2024-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06336889
The ClinicalTrials.gov registry entry for NCT06336889 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Methodist Health System, which has 125 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pelvic Hemorrhage appearing as the primary indexed condition, and to 1 intervention - of which Pelvic Angioembolization is the first listed.
NCT06336889 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06336889 about?
NCT06336889 is a clinical study titled "Pelvic Angioembolization: A Prospective Multi-Institutional Study (Data From All Campuses Will be Used)". The investigator's propose a multicenter prospective observational study to investigate the use of embolization in patients with negative angiogram and to ascertain the optimal level of treatment when the angiogram is positive; non-selective vs. selective embolization.
What is the current status of trial NCT06336889?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2017-10-26. Estimated completion is 2024-10.
What conditions does trial NCT06336889 study?
This clinical trial studies the following conditions: Pelvic Hemorrhage.
What interventions are being tested in trial NCT06336889?
The interventions under investigation include: Pelvic Angioembolization (PROCEDURE).
Who is sponsoring clinical trial NCT06336889?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06336889 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.